FDA Puts Hold on Halozyme Pancreatic Cancer Candidate Trial

Drug Industry Daily
A A
The FDA Tuesday placed a clinical hold on Halozyme Therapeutics’ Phase II study of PEGPH20 for the treatment of pancreatic cancer.

To View This Article:

Login

Subscribe To Drug Industry Daily